India’s first CRISPR Covid-19 test, developed by CSIR & Tata Sons, gets approval


The CRISPR-Cas9-based test developed by CSIR-IGIB in collaboration with Tata Sons recently received regulatory approval from the Drugs Controller General of India (DCGI) for commercial launch, as per ICMR guidelines. The test dubbed FELUDA meets high-quality benchmarks with 96% sensitivity and 98% specificity for detecting the novel coronavirus. The test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus.

The CRISPR test is the world’s first diagnostic test to deploy a specially adapted Cas9 protein to successfully detect the virus causing Covid-19. The ‘Made in India’ test is safe, reliable, affordable, and accessible. It achieves accuracy levels of traditional RT-PCR tests, with quicker turnaround time, less expensive equipment, and better ease of use. Moreover, CRISPR is a futuristic technology that can also be configured for detection of multiple other pathogens in the future...Read more